Gleamer Secures €18M to Develop AI-powered Cancer Diagnostics

Gleamer, a French medtech company focused on AI for medical imaging, announced an €18 million investment in its new project, “OncoView,” to improve cancer diagnostics. The French government also co-funded the initiative with €4.5 million under the France 2030 program, a national initiative to accelerate innovation in key sectors, including healthcare.

OncoView is an AI-based solution that enables radiologists to better and more efficiently interpret oncology CT scans. It helps fill the gap in early cancer detection by improving diagnostic accuracy and addressing the problem of missed lesions, which is one of the biggest challenges in cancer diagnosis. It will also help evaluate treatment outcomes more reliably, contributing to better patient care.

Gleamer’s co-founder and CEO, Christian Allouche, emphasized the importance of AI in the future of radiology, stating, “In ten years, artificial intelligence will be indispensable for interpreting every radiology examination.” He also highlighted that AI improves both productivity and the reliability of diagnoses, making it an essential tool in medical imaging.

€18 million of investment will be provided to support this new AI-based technology for five years. It has also been supported by €4.5 million coming directly from the French government to complement its development. The development supports France 2030’s plan with a budget of €7.5 billion set up for sectors deemed strategic and relevant for France’s future, one of them being healthcare.

The development of OncoView will be done in collaboration with the top French healthcare institutions, industrial partners, and an experienced R&D team focused on AI, data, and clinical research. Lung and bone lesions will be the first focus of OncoView, as these are two of the most common metastatic sites for cancer, providing a foundation for future expansion into other cancer types.

Gleamer’s AI technology, already highly recognized in France and abroad, aims to revolutionize the radiology field. OncoView will complement the company’s current platform, Gleamer Copilot, with advanced AI capabilities, specifically tailored for cancer imaging. This investment will enable Gleamer to accelerate the development of a new generation of AI applications critical to improving cancer detection and monitoring treatment in the years ahead.